Golden ticket? Regeneron, Sanofi buy priority review voucher for alirocumab

Regeneron Pharmaceuticals and Sanofi paid $67.5m to buy BioMarin Pharmaceutical's rare pediatric disease priority review voucher, which could help their cholesterol-reducing therapy alirocumab win US FDA approval before Amgen's competing biologic evolocumab.